Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2011-05-17
2011-05-17
Peng, Bo (Department: 1648)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S235100, C435S325000, C435S005000
Reexamination Certificate
active
07943379
ABSTRACT:
The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, in some embodiments the invention contemplates the use of an adenovirus known as Simian Adenovirus 13 (SAdV-13) and Vero cells for production of recombinant adeno-associated virus (rAAV).
REFERENCES:
patent: 5658785 (1997-08-01), Johnson
patent: 2004/0224411 (2004-11-01), Clark et al.
Li and Samulski, Serotype-specific replicating AAV helper constructs increase recombinant AAV type 2 vector production, 2005, Virology, vol. 335, pp. 10-21.
Adeno-X expression system 1 User Manual, pp. 46-47 (Aug. 2007 version, protocol PT3414-1, version PR7823350), Clontech Laboratories, Inc. (Mountain View, CA).
Aitken et al., “A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease,” Hum Gene Therapy, 12:1907-1916 (2001).
Berkner et al., “Generation of adenovirus by transfection of plasmids,” Nucleic Acids Res 11(17): 6003-20 (1983).
Carter et al., “Adeno-associated Virus and AAV Vectors for Gene Delivery” in Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Second Edition (Ed. N. Templeton-Smith), Chapter 5, pp. 71-101, Marcel Dekker, Inc., New York (2004).
Carter, “Adeno-Associated Virus Helper Functions,” in Handbook of Parvoviruses, vol. I, (P.Tjissen, Ed.) CRC Press, Boca Raton, Chapter 13, pp. 255-282 (1989).
Chen et al., “Molecular Characterization of Adeno-Associated Viruses Infecting Children,” J Virol 79:14781-14792 (2005).
Clark et al., “Highly Purified Recombinant Adeno-Associated Virus Vectors are Biologically Active and Free of Detectable Helper and Wild-Type Viruses,” Hum Gene Ther 10:1031-1039 (1999).
Clark et al., “Cell Lines for the Production of Recombinant Adeno-Associated Virus,” Hum. Gene Ther 6:1329-1341 (1995).
Collaco et al. “A helper virus-free packaging system for recombinant adeno-associated virus vectors,” Gene 238:397-405 (1999).
Conway et al., “High-tier recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap,” Gene Ther 6:986-993 (1999).
Ferrari et al., “Second-Strand Synthesis Is a Rate-Limiting Step for Efficient Transduction by Recombinant Adeno-Associated Virus Vectors,” J Virol 70:3227-3234 (1996).
Fisher et al. “A Novel Adenovirus-Adeno-Associated Virus Hybrid Vector That Displays Efficient Rescue and Delivery of the AAV Genome,” Hum Gene Ther 7:2079-2087 (1996).
Gao et al., “High-Tier Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle Virus,” Hum Gene Ther 9:2353-2362 (1998).
Gao et al., “Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap,” Mol Ther 5:644-649 (2002).
Grimm et al., “Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors,” Hum Gene Ther 9:2745-2760 (1998).
Handa et al., “Adeno-associated Virus DNA Replication Complexes in Herpes Simplex Virus or Adenovirus-infected Cells,” Journal of Biological Chemistry 254(14): 6603-6610 (1979).
Hirt et al., “Selective Extraction of Polyoma DNA from Infected Mouse Cell Cultures,” Journal of Molecular Biology, 26(2): 365-369 (1967).
Inoue et al., “Packaging Cells Based on Inducible Gene Amplification for the Production of Adeno-Associated Virus Vectors,” J Virol 72:7024-7031 (1998).
Kidd et al., “Human and Simian Adenoviruses: Phylogenetic Inferences from Analysis of VA RNA Genes,” Virology 207(1): 32-45 (1995).
Li et al., “Role for Highly RegulatedrepGene Express on in Adeno-Associated Virus Vector Production,” J Virol 71:5236-5243 (1997).
Liu et al., “SelectiveRep-CapGene Amplification as a Mechanism for High-Tier Recombinant AAV Production from Stable Cell Lines,” Mol Ther. 2:394-403 (2000).
Liu et al., “Production of recombinant adeno-associated virus vectors using a packaging cell lines and a hybrid recombinant adenovirus,” Gene Ther. 6:293-299 (1999).
Liu et al., “Efficient Site-Specific Integration of Large Transgenes by an Enhanced Herpes Simplex Virus/Adeno-Associated Virus Hybrid Amplicon Vector,” Journal of Virology 80(4): 1672-1679 (2006).
Matsushita et al., “Adeno-associated virus vectors can be efficiently produced without helper virus,” Gene Ther 5:938-945 (1998).
Muzyczka, “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells,” Current Topics in Microbiology and Immunology, 158: 97-129 (1992).
Ng, et al., “Helper-dependent Adenoviral Vectors for Gene Therapy” in Gene and Cell Therapy, Therapeutic Mechanisms and Strategies, Chapter 4, pp. 53-70, Marcel Dekker, Inc., New York (2004).
Nguyen et al, “Mouse adenovirus (MAV-1) expression in primary human endothelial cells and generation of a full-length infectious plasmid,” Gene Therapy 6:1291-1297 (1999).
Ogasawara et al., “The Use of Heterologous Promoters for Adeno-Associated Virus (AAV) Protein Expression in AAV Vector Production,” Microbiol Immunol 42:177-185 (1998).
Richardson et al., “Vero cells injected with adenovirus type 2 mRNA produce authentic viral polypeptide patterns: Early mRNA promotes growth of adenovirus-associated virus,” Proc Natl Acad Sci USA 77(2): 931-935 (1980).
Ruffing et al., “Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif,” J. Gen. Virol., 75: 3385-3392 (1994).
Salvetti et al., “Factors Influencing Recombinant Adeno-Associated Virus Production,” Hum Gene Ther 9:695-706 (1998).
Schwartz et al., “Adenovirus types 8 and 19 infection of rabbit corneal organ cultures,” Invest Ophthalmol Vis Sci. 18(9):956-63 (1979).
Srivastava et al., “Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome,” J. Virol., 45: 555-564 (1983).
Tamayose et al., “A New Strategy for Large-Scale Preparation of High-Titer Recombinant Adeno-Associated Virus Vectors by Using Packaging Cell Lines and Sulfonated Cellulose Column Chromatography,” Hum Gene Ther 7:507-513 (1996).
Thrasher et al., “Generation of recombinant adeno-associated virus (rAAV) from an adenoviral vector and functional reconstitution of the NADPH-oxidase,” Gene Ther 2:481-485 (1995).
Vincent et al., “Analysis of Recombinant Adeno-Associated Virus Packaging and Requirements forrepandcapGene Products,” J Virol 71:1897-1905 (1997).
Vincent et al., “Modern Approaches to New Vaccines Including Prevention of Aids,” Vaccine 90: 353-359 (1990).
Xiao et al., “Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus,” J Virol 72:2224-2232 (1998).
Beall Clifford J.
Clark Kelly R.
Johnson, Jr. Philip R.
Marshall & Gerstein & Borun LLP
Nationwide Children's Hospital, Inc.
Peng Bo
LandOfFree
Production of rAAV in vero cells using particular adenovirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production of rAAV in vero cells using particular adenovirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of rAAV in vero cells using particular adenovirus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699970